Curis, Inc.

$CRIS - Nasdaq - Pharmaceuticals and Biotechnology
0 LAST
0 CHANGE $
0 CHANGE %
loader
ON 4
WATCHLISTS

COMMUNIQUÉ DETAILS

posts/post

Press Release $CRIS Curis, Inc.

0 COMMENTs 11 Jun
Up 0 0 Down
Curis to Present at the 2013 Wells Fargo Securities Healthcare Conference

LEXINGTON, Mass., June 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the 2013 Wells Fargo Securities Healthcare Conference at 3:30 p.m. ET on June 18, 2013, in Boston.

Dan Passeri, Chief Executive Officer, will provide an overview of Erivedge® (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech that is the first FDA-approved medicine for people with advanced forms of basal cell carcinoma. Mr. Passeri will also provide an overview of Curis' other cancer programs including CUDC-427 and CUDC-907, as well as discuss other corporate activities. 

A corresponding webcast of the presentation can be accessed by visiting:

http://cc.talkpoint.com/well001/061813a_hr/?entity=38_SBV4O67

The presentation will be archived shortly after the live event and available for 30 days following the conference.  In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:
         Michael P. Gray
         Chief Financial Officer
         Curis, Inc.
         617-503-6632
         mgray@curis.com

Source: Curis, Inc.
SHARE THIS: Twitter StockTwits LinkedIn Google Plus SHORT URL: http://bdvt.co/r1b

SIGN IN TO BOARDVOTE

FORGOT PASSWORD?